Novartis To Get Hold Of Fougera For $1.5 Billion For Skin Medications
Thu, 05/03/2012 - 07:11 | 
Swiss pharma giant Novartis stated that it is purchasing dermatology generics firm Fougera for around $1.525 billion, a move that would propel the group to market head spot on generic dermatology medications.
Watson Pharmaceuticals first-quarter income surged 22% as the drug manufacturer announced sharply higher income with a boost from novel generic medications and as its branded pharmaceuticals and distribution biz also registered double-digit growth.
Endo Pharmaceuticals posted a first-quarter loss after assimilating a $110-million pre-tax charge linked to a settlement and license agreement with Impax Laboratories Inc.
Tags: Novartis Makes Alterations To Label Of Multiple Sclerosis Drug
Novartis AG's (NVS) head of pharmaceuticals David Epstein stated that Gilenya will be a smash hit in spite of the improbability surrounding the multiple sclerosis tablet's safety.
SXC Health Solutions Corp stated that will purchase rival pharmacy benefit manager Catalyst Health Solutions Inc for $4.4 billion as it tries to keep pace in the speedily consolidating market for managing Americans' prescriptions.
Research-based pharmaceutical and healthcare firm Glaxosmithkline stated that it has reached deal to sell the previously recognized non-core OTC brands in its global markets to Aspen Pharmacare Holdings Ltd. for GBP164 million in cash.
Novartis To Slash 1960 US Jobs; Glenmark Projects 20% Growth In Sales
Drug manufacturer Novartis will slash around 1,960 jobs in US during 2012 in expectancy of lower sales for two of its high blood pressure medications.
Savient Pharmaceuticals has roped in David Veitch President of Savient Europe with effect from January 16, 2012.
Glenmark Pharmaceuticals projects sales of its speciality biz, which concentrates on branded products, to develop by about 20% in the Indian market by the
coming three years (2015).
Fleming Pharmaceuticals has sold four of its well known brands, comprising Ocean nasal spray, to a division of a Canadian drug firm.
Novartis Recalls Excedrin; Endo Pharma Inks Licensing Deal With BioDelivery
Swiss pharma giant Novartis stated that it was recalling four different medications sold over the counter in the US market following reports of a malfunction at one of its facilities.
Synta Pharmaceuticals is offering 7 million scrips of common stock to the public, with the prospective of making net income of $28.6 million, the company said.
Savient Pharmaceuticals declared that a product-specific billing system, or lasting J-code, for KRYSTEXXA® (pegloticase) became accessible on January 1, 2012.
Endo Pharmaceuticals has decided to pay around $180 million for licensing rights
